Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00401570 | A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer | PHASE2 | COMPLETED | 40 | — | — | Mar 1, 2005 | Jun 1, 2008 | Jan 30, 2013 | 6 | United States, United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Volociximab (10 mg/kg every other week (qowk)) and Gemcitabine |
| Cohort 2 | EXPERIMENTAL | Volociximab (15 mg/kg weekly (qwk)) and Gemcitabine |
| Name | Type | Description |
|---|---|---|
| Volociximab | DRUG | Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks. |
| Gemcitabine | DRUG | Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment |
Inclusion Criteria: * Male or female, 18 years of age or older. * Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas. * May have received prior immunotherapy (including monoclonal antibodies) or vaccine therapies. * Measurable disease, according to RECIST criteria. ...